20141016诱导性多能干细胞技术用于研究人类疾病.doc

诱导性多能干细胞技术用于研究人类疾病 阮光萍 刘菊芬 姚翔 何洁 王金祥 杨建勇 庞荣清 潘兴华* 成都军区昆明总医院干细胞工程实验室（昆明 650032） *通讯作者。Tel: 0871 E-mail: ynkmry@163.comiPS细胞的研究进展，包括iPS细胞的产生，用于治疗，面对的挑战、用于个性化医学和iPS细胞的多能性。 关键词：诱导性多能干细胞；重编程；体细胞；人类疾病 基金资助：国家自然科学基金(批准号:、973计划(批准号: 2012CB518106)(批准号: 201204)和国家支撑计划（批准号：2014BAI01B01）资助的课题。 Induced pluripotent stem cell technology for the study of human diseases Guang-Ping Ruan, Ju-Fen Liu, Xiang Yao, Jie He，Jin-Xiang Wang, Jian-Yong Yang, Rong-Qing Pang, Xing-Hua Pan* Stem Cell Engineering Laboratory, Kunming General Hospital of Chengdu Military Command, Kunming 650032, China *Corresponding author. Tel: +86-871 E-mail: ynkmry@163.com Abstract: Induced pluripotent stem (iPS) cell technology will make patient and disease-specific human cells widely available, but the technical challenges remain, the use of these technologies will greatly amplify our understanding of human diseases. Recent studies show that the expression of four transcription factors which high expression in embryonic stem (ES) cells in vitro, differentiation somatic cells from various mammalian species can reprogram into iPS cells. It has great prospects for application that patient-specific iPS cells from somatic cells generate without oocytes and embryos, when traditional clinical methods for treating a number of diseases are no effect at the current time. However, some recent studies argue various iPS cell lines may remain inherent particular apparent memory in the somatic cells. These studies raised the concern about the safety and efficacies of iPS cells production used in clinical applications. We have recently proved mouse iPS cells have sufficient pluripotency by tetraploid complementation studies, indicating iPS cells obtain full reprogramming from differentiated somatic cells is possible. Therefore, in this review we will discuss iPS cells research progression in recent years, including iPS cells production, use for treatment, faced challenge, use for indi